Abstract:OBJECTIVE:To evaluate the efficacy of cyclosporin A (CSA) in the treatment of idiopathic membranous nephropathy (IMN), a prospective controlled clinical study was performed.METHODS:This study included a group of 30 IMN patients, among them 15 were treated with CSA and 15 with captopril (CAP). The diagnosis of IMN was made with exclusion of secondary forms of membranous nephropathy by extensive clinical and pathological studies. No patients received steroids or cytotoxic agents for six months prior to enrollment. In the CSA group, CSA was given at an initial dosage of 5 mg.kg-1.d-1, gradually tailed off over the first three months and maintained at 2 mg.kg-1.d-1 for 12 months. In the CAP group, CAP was given at a dosage of 37.5 mg/day.RESULTS:In the first three months, 6 (6/15) complete remissions (CR) and 2 (2/15) partial remissions (PR) were observed in the CSA group while only 2 (2/15) PRs were observed in the CAP group. Before the end of the 15-months, 8 patients in the CSA group experienced CR and 4 patients experienced PR. One CR patient relapsed as the dosage of CSA was reduced, so 7 patients remained in CR at the end of the first 15-months. No additional CR or PR was observed in the CAP group during late follow-up. At the last visit (an average follow-up time of 44 months) in the CSA-group, another 2 CR patients had relapsed and 1 CR patient shifted to PR after stopping the CSA treatment, so 4 CR and 5 PR remained in the CSA group. In the CAP group, 3 spontaneous CRs occurred beyond 1.5 year's follow-up, with 3 CR and 2 PR at the last visit. No difference was found between the averages of the initial and the last serum creatinine levels in either group. No serious adverse effects were found during CSA treatment. Re-biopsy data of three patients responsive to CSA treatment showed that no pathological improvement of glomerular basement membrane was observed, even in cases at remission. Tubulointerstitial fibrosis was found in 1 relapsed CR patient, whose serum creatinine increased above the normal range, but not in the other 2 patients whose serum creatinine remained in the normal range.CONCLUSIONS:CSA therapy at a dosage of 5 mg.kg-1.d-1 is effective in inducing remission of nephrotic syndrome in adult IMN patients within three months, with a response rate of 80%. A relatively high rate of relapse (50%) was observed within 2 years after the withdrawal of CSA treatment.

Preliminary observation of low-dose cyclosporine A combined with low-dose prednisone in the treatment of patients with idiopathic membranous nephropathy

Low-Dose Cyclosporine Treatment in Chinese Nephrotic Patients with Idiopathic Membranous Nephropathy: an Uncontrolled Study with Prospective Follow-Up

Tacrolimus Combined with Corticosteroids in Treatment of Nephrotic Idiopathic Membranous Nephropathy: A Multicenter Randomized Controlled Trial

Early Initiation of Tacrolimus or Cyclophosphamide Therapy for Idiopathic Membranous Nephropathy with Severe Proteinuria.

Low-dose Cyclosporine in Treatment of Membranous Nephropathy with Nephrotic Syndrome: Effectiveness and Renal Safety

New-Onset Diabetes Mellitus in Patients with Idiopathic Membranous Nephropathy Undergoing Tacrolimus and Low-Dose Corticosteroid Therapy.

The Efficacy and Safety of Tacrolimus Monotherapy in Adult-Onset Nephrotic Syndrome Caused by Idiopathic Membranous Nephropathy

Cyclosporine A Treatment for Idiopathic Membranous Nephropathy: a Systematic Review and Meta-analysis

Combination Therapy of Prednisone and Cyclophosphamide for Patients with Idiopathic Membranous Nephropathy:A Prospective Randomized Controlled Trial

Cyclosporin A Treatment for Idiopathic Membranous Nephropathy.

Effect of cyclosporine therapy on idiopathic membranous nephropathy presented with refractory nephrotic syndrome

Treatment of idiopathic membranous nephropathy with combination of low-dose tacrolimus and corticosteroids.

Effectiveness and Safety of Cyclophosphamide or Tacrolimus Therapy for Idiopathic Membranous Nephropathy.

Therapy of Tacrolimus Combined with Corticosteroids in Idiopathic Membranous Nephropathy

Tacrolimus Combined with Corticosteroids in Idiopathic Membranous Nephropathy: a Randomized, Prospective, Controlled Trial.

Multitarget therapy with a corticosteroid, cyclosporine and mycophenolate mofetil for idiopathic membranous nephropathy: a prospective randomized controlled trial

Efficacy and Safety of Tacrolimus Vs. Cyclophosphamide for Idiopathic Membranous Nephropathy: A Meta-Analysis of Chinese Adults

CYCLOSPORINE A TREATMENT IN PATIENTS WITH MEMBRANOUS LUPUS NEPHROPATHY

Treatment of nephrotic idiopathic membranous nephropathy with monthly i.v. pulse cyclophosphamide and oral steroids: a single centre's retrospective study.

Comparison of the efficacy and safety of tacrolimus monotherapy and cyclophosphamide combined with glucocorticoid in the treatment of adult primary membranous nephropathy: protocol of a multicenter, randomized, controlled, open study

Cyclosporine A in Treatment of Membranous Lupus Nephropathy